Business
Result of General Meeting and Total Voting Rights
Eden Research plc announced that all resolutions at its General Meeting were passed, approving the Placing, Subscription, and Retail Offer. Directors Lykele van der Broek, Sean Smith, Alex Abrey, and Derek McAllan subscribed for new ordinary shares totaling 1,125,000, 500,000, 500,000, and 250,000 respectively, at 4 pence per share. Following admission on or around February 19, 2026, the company will have 613,362,994 ordinary shares in issue, with each carrying one vote. Disclaimer*
About this update from Eden Research Plc
18 February 2026 Eden Research plc ("Eden Research" or the "Company") Result of General Meeting, Director Shareholdings and Total Voting Rights Eden Research plc (AIM: EDEN), a leader in sustainable biopesticide and biocontrol technologies, announces that all resolutions put to Shareholders at the General Meeting held earlier today in connection with the Placing, Subscription and Retail Offer, as announced by the Company on 2 February 2026, were duly passed. The total number of votes received by proxy on each resolution, as more fully disclosed in the Notice of General Meeting available on the Company's website, was as follows: Resolution For Against Withheld Number of votes % Number of votes % Number of votes % 1 To authorise the Directors to allot relevant securities for cash up to an aggregate nominal amount of £2,787,500, being equal to 278,750,000 New Ordinary Shares 181,446,156 99.51% 901,567 0.49% 2,033,070 - 2 To authorise the Directors to allot 278,750,000 New Ordinary Shares on a non-pre-emptive basis 181,338,467 99.45% 1,001,567 0.55% 2,040,759 - · A vote Withheld is not a vote in law and is not counted in the calculation of the votes cast For or Against the resolution, nor in the calculation of the percentage of issued share capital voted for any resolution. · Votes For and Against are expressed as a percentage of votes validly cast for that resolution by proxy, excluding any Withheld votes. Director Shareholdings The following Directors subscribed for New Ordinary Shares pursuant to the Fundraising. The number of new Ordinary Shares subscribed for by each Director and their resulting shareholdings upon Admission are set out below: Name Number of existing Ordinary Shares Number of Firm Shares subscribed for (1) Number of Ordinary Shares held following Admission Lykele van der Broek 2,357,808 1,125,000 3,482,808 Sean Smith 3,059,768 500,000 3,559,768 Alex Abrey 3,181,678 500,000 3,681,678 Derek McAllan 843,627 250,000 1,093,627 (1) The number of Ordinary Shares presented in this table as being held or subscribed for by Directors refers to the number of Ordinary Shares held or subscribed for by them either personally or through a nominee. The notifications below, made in accordance with the requirements of the UK Market Abuse Regulation, provide further details. Admission and Total Voting Rights Following shareholder approval at the general meeting and conditional on First Admission, a total of 80,010,471 New Ordinary Shares (comprising 74,875,000 Firm Placing Shares, 1,375,000 Firm Subscription Shares and 3,760,471 Retail Offer Shares will be admitted to trading on AIM ("Admission") at 8.00 a.m. on or around 19 February 2026. Following First Admission, the total number of Ordinary Shares in the capital of the Company in issue will be 613,362,994 with each Ordinary Share carrying the right to one vote. There are no shares held in treasury and therefore, following Admission, the total number of voting rights in the Company will be 613,362,994. The above figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure, Guidance and Transparency Rules. Capitalised terms used in this announcement have the meaning given to them in the announcement dated 2 February 2026 and 6 February 2026, unless otherwise defined in this announcement. Enquiries: Eden Research plc www.edenresearch.com Sean Smith Alex Abrey 01285 359 555 Cavendish Capital Markets Limited (Nominated advisor and joint broker) Giles Balleny / Elysia Bough (Corporate Finance) Harriet Ward (Corporate Broking) Dale Bellis (Sales) 020 7220 0500 Oberon Capital (Joint Broker) 020 3179 5300 Nick Lovering Mike Seabrook Adam Pollock Hawthorn Advisors (Financial PR) Victoria Ainsworth [email protected] Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. 1 Details of the person discharging managerial responsibilities / person closely associated a) Name 1. Lykele van der Broek 2. Sean Smith 3. Alex Abrey 4. Derek McAllan 2 Reason for the notification a) Position/status 1. Chairman 2. Chief Executive Officer 3. Chief Financial Officer 4. Non-Executive Director b) Initial notification /Amendment Initial notification 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Eden Research plc b) LEI 213800ZWTYTVQQSM3J85 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Identification code Ordinary Shares of 1 pence each GB0001646941 b) Nature of the transaction 1 & 4: Subscription for New Ordinary Shares 2 & 3: Subscription for New Ordinary Shares through Placing c) Price(s) and volume(s) Price Volume 1 4 pence 1,125,000 2 4 pence 500,000 3 4 pence 500,000 4 4 pence 250,000 d) Aggregated information - Aggregated volume - Price N/A - single transaction e) Date of the transaction 18 February 2026 f) Place of the transaction Outside a trading venue